Bispecific chimeric antigen receptors and methods of use thereof to treat cancer
The invention is directed to a bispecific chimeric antigen receptor, comprising: (a) at least two antigen-specific targeting regions; (b) an extracellular spacer domain; (c) a transmembrane domain; (d) at least one co-stimulatory domain; and (e) an intracellular signaling domain, wherein each antigen-specific targeting region comprises an antigen-specific single chain Fv (scFv) fragment, and binds a different antigen, and wherein the bispecific chimeric antigen receptor is co-expressed with a therapeutic control. The invention also provides methods and uses of the bispecific chimeric antigen receptors.
1. A bispecific chimeric antigen receptor, comprising:
a. at least two antigen-specific targeting regions;
b. an extracellular spacer domain;
c. a transmembrane domain;
d. at least one co-stimulatory domain; and
e. an intracellular signaling domain,
wherein each antigen-specific targeting region comprises a single-domain antibody.
2. The bispecific chimeric antigen receptor of claim 1 , wherein the bispecific chimeric antigen receptor is co-expressed with a therapeutic control.
3. The bispecific chimeric antigen receptor of claim 2 , wherein the therapeutic control comprises any one or more of truncated epidermal growth factor receptor (EGFRt), thymidine kinase, cytosine deaminase, nitroreductase, xanthine-guanine phosphoribosyl transferase, human caspase 8, human caspase 9, purine nucleoside phosphorylase, linamarase/linamarin/glucose oxidase, deoxyribonucleoside kinase, horseradish peroxidase (HRP)/indole-3-acetic (IAA), gamma-glutamylcy steine synthetase, cluster of differentiation (CD)20/alphaCD20, CD34/thymidine kinase chimera, dox-depedent caspase-2, mutant thymidine kinase (HSV-TKSR39), AP1903/Fas system, a chimeric cytokine receptor (CCR), a selection marker, and combinations thereof.
4. The bispecific chimeric antigen receptor of claim 3 , wherein the EGFR t binds any one or more of an EGFR-specific siRNA, a small molecule, an anti-EGFR antibody or a fragment thereof, and a combination thereof.
5. The bispecific chimeric antigen receptor of claim 3 , wherein the selection marker comprises any one or more of dihydroxyfolate receptor (DHFR), mutant DHFR, methylated-DNA-protein-cysteine methyltransferase, inosine monophosphate dehydrogenase II (IMDHP2) and combinations thereof.
6. The bispecific chimeric antigen receptor of claim 3 , wherein the CCR comprises any one or more of (i) interleukin (IL)-7 cytokine-linker-IL7Rα, (ii) IL-7 cytokine-linker-extracellular domain of IL-7Rα-transmembrane domain of IL-7Rα-cytoplasmic domain of IL-2Rβ, (iii) IL-7 cytokine-linker-IL2Rβ, and (iv) combinations thereof.
7. The bispecific chimeric antigen receptor of claim 2 , wherein the bispecific chimeric antigen receptor and the therapeutic control are linked via a cleavable linker.
8. The bispecific chimeric antigen receptor of claim 7 , wherein the cleavable linker is a self-cleaving cleavable linker.
9. The bispecific chimeric antigen receptor of claim 8 , wherein the cleavable linker is a 2A linker or a 2A-like linker.
10. The bispecific chimeric antigen receptor of claim 1 , wherein the extracellular spacer domain comprises any one or more of an Fc fragment of an antibody, a hinge region of an antibody, a constant domain of heavy chain (CH)2 region of an antibody, a CH3 region of an antibody, and combinations thereof.
11. The bispecific chimeric antigen receptor of claim 10 , wherein the extracellular spacer domain comprises any one or more of (i) a hinge, CH2 and CH3 region of immunoglobulin G4 (IgG4), (ii) a hinge region of IgG4, (iii) a hinge and CH2 region of IgG4, (iv) a hinge region of CD8α, (v) a hinge, CH2 and CH3 region of IgG1, (vi) a hinge region of IgG1, (vii) a hinge and CH2 region of IgG1, and (viii) combinations thereof.
12. The bispecific chimeric antigen receptor of claim 1 , wherein the transmembrane domain comprises a transmembrane region of a Type I transmembrane protein.
13. The bispecific chimeric antigen receptor of claim 12 , wherein the transmembrane domain comprises any one or more of a transmembrane domain of a zeta chain of a T cell receptor complex, CD28, CD8α, and combinations thereof.
14. The bispecific chimeric antigen receptor of claim 1 , wherein the co-stimulatory domain comprises a signaling domain from any one or more of CD28, CD137 (4-1BB), CD134 (OX40), Dap10, CD27, CD2, CD5, intercellular adhesion molecule 1 (ICAM-1), lymphocyte function-associated antigen 1 (LFA-1), Lck, tumor necrosis factor receptor type I (TNFR-I), TNFR-II, Fas, CD30, CD40 and combinations thereof.
15. The bispecific chimeric antigen receptor of claim 1 , wherein the intracellular signaling domain comprises a signaling domain of one or more of a human CD3 zeta chain, FcγRIII, FcεRI, a cytoplasmic tail of a Fc receptor, an immunoreceptor tyrosine-based activation motif (ITAM) bearing cytoplasmic receptors, and combinations thereof.
16. The bispecific chimeric antigen receptor of claim 1 , wherein each of the at least two antigen-specific targeting domains, independently, targets an antigen selected from the group consisting of antigens specific for cancer, an inflammatory disease, a neuronal disorder, diabetes, a cardiovascular disease, an infectious disease, and an autoimmune disease.
17. The bispecific chimeric antigen receptor of claim 16 ,wherein the antigens specific for cancer comprise any one or more of 4-1BB, 5T4, adenocarcinoma antigen, alpha-fetoprotein, B-cell activating factor (BAFF), B-lymphoma cell, C242 antigen, CA-125, carbonic anhydrase 9 (CA-IX), C-mesenchymal to epithelial transition (MET), C-C chemokine receptor type 4 (CCR4), CD152, CD19, CD20, CD200, CD22, CD221, CD23 (IgE receptor), CD28, CD30 (TNFRSF8), CD33, CD4, CD40, CD44 v6, CD51, CD52, CD56, CD74, CD80, carcinoembryonic antigen (CEA), carlumab (CNTO0888), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), death receptor 5 (DR5), EGFR, epithelial cell adhesion molecule (EpCAM), CD3, fibroblast activation protein (FAP), fibronectin extra domain-B, folate receptor 1, disialoganglioside (GD)2, GD3ganglioside, glycoprotein 75, glycoprotein non-metastatic b (GPNMB), human epidermal growth factor receptor2(HER2)/neu, hepatocyte growth factor (HGF), human scatter factor receptor kinase, insulin-like growth factor 1(IGF-1) receptor, IGF-I, IgG1, L1 cell adhesion molecule (L1-CAM), IL-13, IL-6, integrin α5β1, integrin αvβ3, amatuximab (MORAb-009), membrane spanning 4-domains A1 (MS4A1), mucin 1 (MUC1), mucin CanAg, N-glycolylneuraminic acid, NPC-1C, platelet-derived growth factor receptor α (PDGF-R α), enavatuzumab (PDL192), phosphatidylserine, prostatic carcinoma cells, receptor activator of nuclear factor kappa-B ligand (RANKL), récepteur d'origine nantais (RON), receptor tyrosine kinase-like orphan receptor (ROR1), SCH 900105, syndecan-1 (SDC1), signaling lymphocytic activation molecule (SLAM) F7, tumor-associated glycoprotein 72 (TAG-72), tenascin C, transforming growth factor (TGF) beta 2, TGF-β, TNF-related apoptosis inducing ligand receptor 1 (TRAIL-R1), TRAIL-R2, tumor antigen CTAA16.88, vascular endothelial growth factor (VEGF)-A, VEGFR-1, VEGFR2, vimentin, and combinations thereof.
18. The bispecific chimeric antigen receptor of claim 1 , wherein each antigen-specific targeting region binds a different antigen.
19. The bispecific chimeric antigen receptor of claim 18 , wherein the at least two antigen-specific targeting regions bind (i) CD19and CD20, (ii) CD20 and L1-CAM, (iii) L1-CAM and GD2, (iv) EGFR and L1-CAM, (v) CD19 and CD22, (vi) EGFR and C-MET, (vii) EGFR and HER2, (viii) C-MET and HER2, or (ix) EGFR and ROR1.
20. The bispecific chimeric antigen receptor of claim 18 , wherein the at least two antigen-specific targeting regions bind CD19 and CD20.
21. The bispecific chimeric antigen receptor of claim 16 , wherein the antigen specific for an inflammatory disease comprises any one or more of amine oxidase copper containing 3 (AOC3) (VAP-1), mavrilimumab (CAM-3001), C-C motif chemokine (CCL)11(eotaxin-1), CD125, CD147 (basigin), CD154 (CD40L), CD2, CD20, CD23 (IgE receptor), CD25 (α chain of IL-2 receptor), CD3, CD4, CD5, interferon (IFN)-α, IFN-γ, IgE, IgE Fc region, IL-1, IL-12, IL-23, IL-13, IL-17, IL-17A, IL-22, IL-4, IL-5, IL-5, IL-6, IL-6 receptor, integrin α4, integrin α4β7,LFA-1(CD11a), MEDI-528, myostatin, OX-40 (CD134), rhuMAb β7, scleroscin, sclerostin (SOST), TGF beta 1, TNF-α, VEGF-A, and combinations thereof.
22. The bispecific chimeric antigen receptor of claim 16 , wherein the antigen specific for a neuronal disorder comprises beta amyloid, crenezumab (MABT5102A), or a combination thereof.
23. The bispecific chimeric antigen receptor of claim 16 , wherein the antigen specific for diabetes comprises IL-1β, CD3, or a combination thereof.
24. The bispecific chimeric antigen receptor of claim 16 , wherein the antigen-specific for a cardiovascular disease comprises any one or more of fifth component of complement (C5), cardiac myosin, CD41 (integrin alpha-IIb), fibrin II, beta chain, integrin beta 2 (ITGB2) (CD18), sphingosine-1- phosphate, and combinations thereof.
25. The bispecific chimeric antigen receptor of claim 16 , wherein the antigen specific for an infectious disease comprises any one or more of anthrax toxin, CCR5, CD4, clumping factor A, cytomegalovirus, cytomegalovirus glycoprotein B, endotoxin, Escherichia coli , hepatitis B surface antigen, hepatitis B virus, HIV-1, Hsp90, Influenza A hemagglutinin, lipoteichoic acid, Pseudomonas aeruginosa , rabies virus glycoprotein, respiratory syncytial virus, TNF-α, and combinations thereof.
26. A composition comprising the bispecific chimeric antigen receptor of claim 1 and a therapeutic control.
27. The combination of claim 26 , wherein the therapeutic control comprises any one or more of truncated epidermal growth factor receptor (EGFRt), thymidine kinase, cytosine deaminase, nitroreductase, xanthine-guanine phosphoribosyl transferase, human caspase 8, human caspase 9, purine nucleoside phosphorylase, linamarase/linamarin/glucose oxidase, deoxyribonucleoside kinase, horseradish peroxidase (HRP)/indole- 3 -acetic (IAA), gamma-glutamylcysteine synthetase, CD20/alphaCD20, CD34/thymidine kinase chimera, dox-depedent caspase-2, mutant thymidine kinase (HSV-TKSR39), AP1903/Fas system, a chimeric cytokine receptor (CCR), a selection marker, and combinations thereof.
28. The combination of claim 27 , wherein the EGFRt binds any one or more of an EGFR-specific siRNA, a small molecule, an anti-EGFR antibody or a fragment thereof, or a combination thereof.
29. The combination of claim 27 , wherein the selection marker comprises any one or more of dihydroxyfolate receptor (DHFR), mutant DHFR, methylated-DNA-protein-cysteine methyltransferase, inosine monophosphate dehydrogenase II (IMDHP2) and combinations thereof.
30. The combination of claim 27 , wherein the CCR comprises any one or more of (i) IL-7 cytokine-linker-IL7Rα, (ii) IL-7 cytokine-linker-extracellular domain of IL-7Rα-transmembrane domain of IL-7Rα-cytoplasmic domain of IL-2Rβ, (iii) IL-7 cytokine-linker-IL2Rβ, and (iv) combinations thereof.
31. The combination of claim 26 , wherein the bispecific chimeric antigen receptor and the therapeutic control are linked via a cleavable linker.
32. The combination of claim 31 , wherein the cleavable linker is a self-cleaving cleavable linker.
33. The combination of claim 31 , wherein the cleavable linker is a 2A linker or a 2A-like linker.
34. A polypeptide encoded by a polynucleotide encoding the bispecific chimeric antigen receptor of claim 1 or the combination of claim 26 .
35. A pharmaceutical composition, comprising:
a. the bispecific chimeric antigen receptor of claim 1 , the combination of claim 26 , the polypeptide of claim 34 , or a combination thereof; and
b. a pharmaceutically acceptable carrier.
36. In combination, the pharmaceutical composition of claim 35 and a composition adapted to biochemically interact with the therapeutic control to inhibit proliferation of a cell expressing the therapeutic control.
37. The combination of claim 36 , wherein the composition adapted to biochemically interact with the therapeutic control is any one or more of trastuzumab, methotrexate, cetuximab, ganciclovir, (E)-5-(2-bromovinyl)-2′-deoxyuridine (BVDU), 5-flurocytosine (5-FC), 5-(azaridin-l-yl)-2, 4-dinitrobenzamide (CB1954), 6-thioguanine, AP1903, fludarabine phosphate, linamarin (lin), difluorodeoxycytidine (dFdC), 1-β-D-arabinofuranosylthymine (ara-T)), indole-3-acetic (IAA), 1-buthionine-S,R-sulfoximine (BSO), rituximab (RTX), doxycycline, tyrosine kinase inhibitors and combinations thereof.
38. A bispecific chimeric antigen receptor, comprising:
a. at least two antigen-specific targeting regions;
b. an extracellular spacer domain;
c. a transmembrane domain;
d. at least one co-stimulatory domain; and
e. an intracellular signaling domain,
wherein each antigen-specific targeting region comprises a single-domain antibody, and
wherein each antigen-specific targeting region binds a different antigen.
39. The bispecific chimeric antigen receptor of claim 38 , wherein the bispecific chimeric antigen receptor is co-expressed with a therapeutic control, the therapeutic control comprising any one or more of EGFRt, thymidine kinase, cytosine deaminase, nitroreductase, xanthine-guanine phosphoribosyl transferase, human caspase 8, human caspase 9, purine nucleoside phosphorylase, linamarase/linamarin/glucose oxidase, deoxyribonucleoside kinase, horseradish peroxidase (HRP)/indole-3-acetic (IAA), gamma-glutamylcysteine synthetase, CD20/alphaCD20, CD34/thymidine kinase chimera, dox-depedent caspase-2, mutant thymidine kinase (HSV-TKSR39), AP1903/Fas system, a chimeric cytokine receptor (CCR), a selection marker, and combinations thereof.
40. The bispecific chimeric antigen receptor of claim 39 , wherein the therapeutic control comprises EGFRt.
41. The bispecific chimeric antigen receptor of claim 40 , wherein the EGFRt binds any one or more of an EGFR-specific siRNA, a small molecule, an anti-EGFR antibody or a fragment thereof, and a combination thereof.
42. The bispecific chimeric antigen receptor of claim 39 , wherein the selection marker comprises any one or more of dihydroxyfolate receptor (DHFR), mutant DHFR, methylated-DNA-protein-cysteine methyltransferase, inosine monophosphate dehydrogenase II (IMDHP2) and combinations thereof.
43. The bispecific chimeric antigen receptor of claim 39 , wherein the CCR comprises any one or more of (i) IL-7cytokine-linker-IL7Rα, (ii) IL-7 cytokine-linker-extracellular domain of IL-7Rα-transmembrane domain of IL-7Rα-cytoplasmic domain of IL-2Rβ, (iii) IL-7 cytokine-linker-IL2Rβ, and (iv) combinations thereof.
44. The bispecific chimeric antigen receptor of claim 39 , wherein the bispecific chimeric antigen receptor and the therapeutic control are linked via a cleavable linker.
45. The bispecific chimeric antigen receptor of claim 44 , wherein the cleavable linker is a self-cleaving cleavable linker.
46. The bispecific chimeric antigen receptor of claim 44 , wherein the cleavable linker is a 2A linker or a 2A-like linker.
47. The bispecific chimeric antigen receptor of claim 38 , wherein the extracellular spacer domain comprises any one or more of an Fc fragment of an antibody, a hinge region of an antibody, a CH2 region of an antibody, a CH3 region of an antibody, and combinations thereof.
48. The bispecific chimeric antigen receptor of claim 47 , wherein the extracellular spacer domain comprises any one or more of (i) a hinge, CH2 and CH3 region of IgG4, (ii) a hinge region of IgG4, (iii) a hinge and CH2 region of IgG4, (iv) a hinge region of CD8α(v) a hinge, CH2 and CH3 region of IgG1, (vi) a hinge region of IgG1, (vii) a hinge and CH2 region of IgG1, and (viii) combinations thereof.
49. The bispecific chimeric antigen receptor of claim 38 , wherein the transmembrane domain comprises a transmembrane region of a Type I transmembrane protein, an artificial hydrophobic sequence, or a combination thereof.
50. The bispecific chimeric antigen receptor of claim 49 , wherein the transmembrane domain comprises any one or more of a transmembrane domain of a zeta chain of a T cell receptor complex, CD28, CD8α, and combinations thereof.
51. The bispecific chimeric antigen receptor of claim 38 , wherein the co-stimulatory domain comprises a signaling domain from any one or more of CD28, CD137 (4-1BB), CD134 (OX40), Dap10, CD27, CD2, CD5, ICAM-1, LFA-1, Lck, TNFR-I, TNFR-II, Fas, CD30, CD40 and combinations thereof.
52. The bispecific chimeric antigen receptor of claim 38 , wherein the intracellular signaling domain comprises a signaling domain of one or more of a human CD3 zeta chain, FcγRIII, FcεRI, a cytoplasmic tail of a Fc receptor, an immunoreceptor tyrosine-based activation motif (ITAM) bearing cytoplasmic receptors, and combinations thereof.
53. The bispecific chimeric antigen receptor of claim 38 , wherein each of the at least two antigen-specific targeting domains, independently, targets an antigen selected from the group consisting of antigens specific for cancer, an inflammatory disease, a neuronal disorder, diabetes, a cardiovascular disease, an infectious disease, and an autoimmune disease.
54. The bispecific chimeric antigen receptor of claim 53 , wherein the antigens specific for cancer comprise any one or more of 4-1BB, 5T4, adenocarcinoma antigen, alpha-fetoprotein, BAFF, B-lymphoma cell, C242antigen, CA-125, carbonic anhydrase 9 (CA-IX), C-MET, CCR4, CD152, CD19, CD20, CD200, CD22, CD221, CD23 (IgE receptor), CD28, CD30(TNFRSF8), CD33, CD4, CD40, CD44 v6, CD51, CD52, CD56, CD74, CD80, CEA, CNTO888, CTLA-4, DR5, EGFR, EpCAM, CD3, FAP, fibronectin extra domain-B, folate receptor 1, GD2, GD3 ganglioside, glycoprotein 75, GPNMB, HER2/neu, HGF, human scatter factor receptor kinase, IGF-1 receptor, IGF-I, IgG1, L1-CAM, IL-13, IL-6, insulin-like growth factor I receptor, integrin α5β1, integrin αvβ3, MORAb-009, MS4A1, MUC1, mucin CanAg, N-glycolylneuraminic acid, NPC-1C, PDGF-R α, PDL192, phosphatidylserine, prostatic carcinoma cells, RANKL, RON, ROR1, SCH 900105, SDC1, SLAMF7, TAG-72, tenascin C, TGF beta 2, TGF-β, TRAIL-R1, TRAIL-R2, tumor antigen CTAA16.88, VEGF-A, VEGFR-1, VEGFR2, vimentin, and combinations thereof.
55. The bispecific chimeric antigen receptor of claim 38 , wherein the at least two antigen-specific targeting regions bind (i) CD19and CD20, (ii) CD20 and L1-CAM, (iii) L1-CAM and GD2, (iv) EGFR and L1-CAM, (v) CD19 and CD22, (vi) EGFR and C-MET, (vii) EGFR and HER2, (viii) C-MET and HER2, or (ix) EGFR and ROR1.
56. The bispecific chimeric antigen receptor of claim 38 , wherein the at least two antigen-specific targeting regions bind CD19 and CD20.
57. The bispecific chimeric antigen receptor of claim 53 , wherein the antigen specific for an inflammatory disease comprises any one or more of AOC3 (VAP-1), CAM-3001, CCL11 (eotaxin-1), CD125, CD147 (basigin), CD154 (CD40L), CD2, CD20, CD23 (IgE receptor), CD25 (α chain of IL-2 receptor), CD3, CD4, CD5, IFN-α, IFN-γ, IgE, IgE Fc region, IL-1, IL-12, IL-23, IL-13, IL-17, IL-17A, IL-22, IL-4, IL-5, IL-5, IL-6, IL-6 receptor, integrin α4, integrin α4β7, LFA-1 (CD11a), MEDI-528, myostatin, OX-40, rhuMAb β7, scleroscin, SOST, TGF beta 1, TNF-α, VEGF-A, and combinations thereof.
58. The bispecific chimeric antigen receptor of claim 53 , wherein the antigen specific for a neuronal disorder comprises beta amyloid, MABT5102A, or a combination thereof.
59. The bispecific chimeric antigen receptor of claim 53 , wherein the antigen specific for diabetes comprises L-1β, CD3, or a combination thereof.
60. The bispecific chimeric antigen receptor of claim 53 , wherein the antigen-specific for a cardiovascular disease comprises any one or more of C5, cardiac myosin, CD41 (integrin alpha-IIb), fibrin II, beta chain, ITGB2 (CD18), sphingosine-1-phosphate, and combinations thereof.
61. The bispecific chimeric antigen receptor of claim 53 , wherein the antigen specific for an infectious disease comprises any one or more of anthrax toxin, CCR5, CD4, clumping factor A, cytomegalovirus, cytomegalovirus glycoprotein B, endotoxin, Escherichia coli , hepatitis B surface antigen, hepatitis B virus, HIV-1, Hsp90, Influenza A hemagglutinin, lipoteichoic acid, Pseudomonas aeruginosa , rabies virus glycoprotein, respiratory syncytial virus, TNF-α, and combinations thereof.
62. In combination, the bispecific chimeric antigen receptor of claim 40 and the EGFRt.
63. The combination of claim 62 , wherein the EGFRt binds any one or more of an EGFR-specific siRNA, a small molecule, an anti-EGFR antibody or a fragment thereof, or a combination thereof.
64. The combination of claim 62 , wherein the bispecific chimeric antigen receptor and the EGFRt are linked via a cleavable linker.
65. The combination of claim 64 , wherein the cleavable linker is a self-cleaving cleavable linker.
66. The combination of claim 64 , wherein the cleavable linker is a 2A linker or a 2A-like linker.
67. A polypeptide encoded by a polynucleotide encoding the bispecific chimeric antigen receptor of claim 38 or the combination of claim 62 .
68. A pharmaceutical composition, comprising:
a. any one or more of the bispecific chimeric antigen receptor of claim 38 , the combination of claim 62 , the polypeptide of claim 67 , and combinations thereof; and
b. a pharmaceutically acceptable carrier.
69. In combination, the pharmaceutical composition of claim 68 and a composition adapted to biochemically interact with the therapeutic control to inhibit proliferation of a cell expressing the EGFRt.
70. A method for treating cancer in a subject in need thereof, comprising:
administering a therapeutically effective amount of the composition of claim 68 to the subject so as to treat the cancer,
wherein the at least two antigen-specific targeting regions target at least one antigen associated with the cancer.
71. A bispecific chimeric antigen receptor comprising the sequence set forth in SEQ ID NO: 2, 8 or 11.
72. A bispecific chimeric antigen receptor, comprising:
a. at least two antigen-specific targeting regions;
b. a CD8α hinge extracellular spacer domain;
c. a CD8α transmembrane domain;
d. a 4-1BB co-stimulatory domain; and
e. a CD3 zeta intracellular signaling domain,
wherein each antigen-specific targeting region comprises a single-domain antibody.
73. The bispecific chimeric antigen receptor of claim 72 , wherein the bispecific chimeric antigen receptor is co-expressed with a therapeutic control, the therapeutic control comprising any one or more of EGFRt, thymidine kinase, cytosine deaminase, nitroreductase, xanthine-guanine phosphoribosyl transferase, human caspase 8, human caspase 9, purine nucleoside phosphorylase, linamarase/linamarin/glucose oxidase, deoxyribonucleoside kinase, horseradish peroxidase (HRP)/indole-3-acetic (IAA), gamma-glutamylcysteine synthetase, CD20/alphaCD20, CD34/thymidine kinase chimera, dox-depedent caspase-2, mutant thymidine kinase (HSV-TKSR39), AP1903/Fas system, a chimeric cytokine receptor (CCR), a selection marker, and combinations thereof.
74. The bispecific chimeric antigen receptor of claim 73 , wherein the EGFRt binds any one or more of an EGFR-specific siRNA, a small molecule, an anti EGFR antibody or a fragment thereof, and a combination thereof.
75. The bispecific chimeric antigen receptor of claim 73 , wherein the selection marker comprises any one or more of dihydroxyfolate receptor (DHFR), mutant DHFR, methylated-DNA-protein-cysteine methyltransferase, inosine monophosphate dehydrogenase II (IMDHP2) and combinations thereof.
76. The bispecific chimeric antigen receptor of claim 73 , wherein the CCR comprises any one or more of (i) IL-7 cytokine-linker- IL7Rα, (ii) IL-7 cytokine-linker-extracellular domain of IL-7Rα-transmembrane domain of IL-7Rαcytoplasmic domain of IL-2Rβ, (iii) IL-7cytokine-linker-IL2Rβ, and (iv) combinations thereof.
77. The bispecific chimeric antigen receptor of claim 72 , wherein each of the at least two antigen-specific targeting domains, independently, targets an antigen selected from the group consisting of antigens specific for cancer, an inflammatory disease, a neuronal disorder, diabetes, a cardiovascular disease, an infectious disease, and an autoimmune disease.
78. The bispecific chimeric antigen receptor of claim 77 , wherein the antigen specific for cancer comprises any one or more of 4-1BB, 5T4, adenocarcinoma antigen, alpha-fetoprotein, BAFF, B-lymphoma cell, C242 antigen, CA-125, carbonic anhydrase 9 (CA-IX), C-MET, CCR4, CD152, CD19, CD20, CD200, CD22, CD221, CD23 (IgE receptor), CD28, CD30 (TNFRSF8), CD33, CD4, CD40, CD4 v6, CD51, CD52, CD56, CD74, CD80, CEA, CNTO888, CTLA-4, DR5, EGFR, EpCAM, CD3, FAP, fibronectin extra domain-B, folate receptor 1, GD2, GD3 ganglioside, glycoprotein 75, GPNMB, HER2/neu, HGF, human scatter factor receptor kinase, IGF-1 receptor, IGF-I, IgG1, L1-CAM, IL-13, IL-6, insulin-like growth factor I receptor, integrin α5β1, integrin αvβ3, MORAb-009, MS4A1, MUC1, mucin CanAg, N-glycolylneuraminic acid, NPC-1C, PDGF-R α, PDL192, phosphatidylserine, prostatic carcinoma cells, RANKL, RON, ROR1, SCH 900105, SDC1, SLAMF7, TAG-72, tenascin C, TGF beta 2, TGF-β, TRAIL-R1, TRAIL-R2, tumor antigen CTAA16.88, VEGF-A, VEGFR-1, VEGFR2, vimentin, and combinations thereof.
79. The bispecific chimeric antigen receptor of claim 77 , wherein the at least two antigen-specific targeting regions bind (i) CD19 and CD20, (ii) CD20 and L1-CAM, (iii) L1-CAM and GD2, (iv) EGFR and L1-CAM, (v) CD19 and CD22, (vi) EGFR and C-MET, (vii) EGFR and HER2, (viii) C-MET and HER2, or (ix) EGFR and ROR1.
80. The bispecific chimeric antigen receptor of claim 79 , wherein the at least two antigen-specific targeting regions bind CD19 and CD20.
81. The bispecific chimeric antigen receptor of claim 77 , wherein the antigen specific for an inflammatory disease comprises any one or more of AOC3 (VAP-1), CAM-3001, CCL11 (eotaxin-1), CD125, CD147 (basigin), CD154 (CD40L), CD2, CD20, CD23 (IgE receptor), CD25 (α chain of IL-2 receptor), CD3, CD4, CD5, IFN-αIFN-γIgE, IgE Fc region, IL-1, IL-12, IL-23, IL-13, IL-17, IL-17A, IL-22, IL-4, IL-5, IL-5, IL-6, IL-6 receptor, integrin α4, integrin α4β7, LFA-1 (CD11a), MEDI-528, myostatin, OX-40, rhuMAb β7, scleroscin, SOST, TGF beta 1, TNF-α, VEGF-A, and combinations thereof.
82. The bispecific chimeric antigen receptor of claim 77 , wherein the antigen specific for a neuronal disorder comprises beta amyloid, MABT5102A, or a combination thereof.
83. The bispecific chimeric antigen receptor of claim 77 , wherein the antigen specific for diabetes comprises L-1β, CD3, or a combination thereof.
84. The bispecific chimeric antigen receptor of claim 77 , wherein the antigen-specific for a cardiovascular disease comprises any one or more of C5, cardiac myosin, CD41 (integrin alpha-IIb), fibrin II, beta chain, ITGB2 (CD18) , sphingosine-1-phosphate, and combinations thereof.
85. The bispecific chimeric antigen receptor of claim 77 , wherein the antigen specific for an infectious disease comprises any one or more of anthrax toxin, CCR5, CD4, clumping factor A, cytomegalovirus, cytomegalovirus glycoprotein B, endotoxin, Escherichia coli , hepatitis B surface antigen, hepatitis B virus, HIV-1, Hsp90, Influenza A hemagglutinin, lipoteichoic acid, Pseudomonas aeruginosa , rabies virus glycoprotein, respiratory syncytial virus, TNF-a, and combinations thereof.
86. A method for treating cancer in a subject in need thereof, comprising:
administering a therapeutically effective amount of the composition of claim 35 to the subject so as to treat the cancer,
wherein the at least two antigen-specific targeting regions target at least one antigen that is associated with the cancer.
87. The combination of claim 69 , wherein the composition adapted to biochemically interact with the therapeutic control is any one or more of trastuzumab, methotrexate, cetuximab, ganciclovir, (E)-5-(2-bromovinyl)-2′-deoxyuridine (BVDU), 5-flurocytosine (5-FC), 5-(azaridin-l-yl)-2, 4-dinitrobenzamide (CB1954), 6-thioguanine, AP1903, fludarabine phosphate, linamarin (lin), difluorodeoxycytidine (dFdC), 1-β-D-arabinofuranosylthymine (ara-T)), indole-3-acetic (IAA), 1-buthionine-S,R-sulfoximine (BSO), rituximab (RTX), doxycycline, tyrosine kinase inhibitors or combinations thereof.